Tags: Life Sciences
Webinar Video | Life Sciences Session #2: Vaccine liability: what if vaccination goes wrong?
The ongoing vaccination campaign against Covid-19 raises the question of possible side effects and of the potential liability for damages arising from the use of vaccines used against this disease.
Precaution is not enough – CJEU finds that Cannabidiol (CBD) is not a narcotic drug
The legal status of CBD, a naturally occurring compound found in the cannabis plant, is murky. The Court has ruled that CBD is not a narcotic drug and that the principles of free movement apply.
Webinar Video | Life Sciences Session #1: What’s new in the parallel world of parallel trade?
In our first Life Sciences Session, our experts Philippe de Jong and Kirian Claeyé talk you through a number of recent decisions and developments in the field of parallel trade of pharmaceuticals, medical devices and plant protection products.
TRIS procedure further clarified by the Court of Justice in two recent rulings of 8 October 2020
The Court of Justice of the EU has shed light on Directive 2015/1535 (TRIS) in two recent rulings of 8 October 2020. They explain when a national law triggers the notification procedure and clarify the interrelationship with a notification under another piece of EU law.
Can a parallel importer rebrand generic medicines?
If a branded medicine and its generic version are put on the EEA market by economically-linked undertakings, is a parallel importer then allowed to rebrand and repackage the imported generic version as the branded reference medicine?
Food labelling – National rules on mandatory indication of the country of origin
This is the third decision of the CJEU on the concept of “country of origin” in a (bit more than a) year.
Webinar Video | Lunch & Learn: Life Sciences : Morceaux choisis
Ce webinar porte sur les sciences du vivant et est composé de deux parties: ‘Ecueils et dangers pour la protection de la recherche & du développement dans le secteur du vivant: préceptes de bonne hygiène juridique’ et Vente de produits de produits de santé et de médicaments aux hôpitaux : les points d’attention en droit des marchés publics”.
The Belgian Competition Authority confirms that Belgian merger control rules apply to the creation of loco-regional hospital networks pursuant to the Act of 28 February 2019
Following the recent legislative amendment obliging hospitals to establish and be part of a loco-regional hospital network, the Belgian Competition Authority published on 22 July 2020 a note setting out the principles that will guide it when assessing the establishment of hospital networks and their possible qualification as a concentration under competition law.
Belgian federal government restricts the sale of personal protective equipment and medical devices that can be used in the fight against Covid-19 – Updated
On 23 March 2020, a Ministerial Decree on special measures in the context of the SARS-CoV-2 pandemic on the basis of Book XVIII of the Code of Economic Law was adopted by the Belgian Minister of Economic Affairs, which restricts both the retail and wholesale distribution of certain types of personal protective equipment, as well as of medical devices used for treating Covid-19 patients.
EC has adopted temporary derogations from certain EU competition rules
On 30 April 2020, the European Commission adopted three implementing regulations allowing temporary derogations from the strict cartel prohibition provided for by EU competition law in three specific agricultural sectors: dairy, potato and live plants and flowers.
Belgium takes measures to avoid medicine shortages during the COVID-19 pandemic
On 8 April 2020, the Belgian federal agency for medicines and health products adopted a consolidated version of its decision taking the following urgent measures for certain listed medicines to avoid medicine shortages during the SARS-CoV-2 pandemic.
Reimbursement of medicinal products in times of pandemics and budgetary constraints: why quick fixes do not work
With national governments scrambling to take measures in order to counter the Covid-19 pandemic, we are again confronted with the fact that a EU common policy in the healthcare field is quasi inexistent.